Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma

Sponsor
GlaxoSmithKline
Study ID
NCT03763370
Status
Available

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd) — DRUG
    Drug: Belantamab mafodotin •Belantamab mafodotin 2.5 milligram per kilogram (mg/kg) intravenous (IV) will be administered at every cycle, once every 3 Weeks, on Day 1 of every cycle, until completion of treatment. Drug: Bortezomib •Bortezomib will be administered based on the full prescribing information, for the first 8 Cycles Drug: Dexamethasone •Dexamethasone will be administered based on the full prescribing information, for the first 8 Cycles
  • Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd) — DRUG
    Drug: Belantamab mafodotin: * Cycle 1: Belantamab mafodotin 2.5 mg/kg IV administered once * Cycle 2 onward: Belantamab mafodotin 1.9 mg/kg IV administered once every 4 weeks until completion of treatment Drug: Pomalidomide •Pomalidomide will be administered at every cycle, based on the full prescribing information Drug: Dexamethasone •Dexamethasone will be administered at every cycle, based on the full prescribing information

Study Details

Compassionate use access to belantamab mafodotin (GSK2857916) (in combination with bortezomib/dexamethasone or pomalidomide/dexamethasone) for eligible participants with multiple myeloma previously treated with at least 1 prior line of therapy.

Key Dates

Status verified
Oct 2024

Central Contacts

Related Studies